Company Analysis
Sign in

Regenxbio Inc. (RGNX)

Nasdaq: RGNX · Biological Products, (No Diagnostic Substances) · Rockville, MD · filing with the SEC since 2013
Full chart Alerts Compare
Grade5.6
◀ Past 7.0● Present 5.4▶ Future 4.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Regenxbio Inc.’s names, not what it holds today.

Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 4 in 2024 and 1 in 2023
Applications published
98
21 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Chemical engineering1
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
REGENXBIO Inc. its own name
named as the applicant on its applications, in US
0 granted
86 published
REGENXBIO INC. its own name
US, as the owner printed on each patent
8 granted
12 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 22, 202512,365,865Scalable clarification process for recombinant AAV productionBiotechnologyREGENXBIO INC.
Mar 11, 202512,247,213Treatment of mucopolysaccharidosis IVAPharmaceuticalsREGENXBIO INC.
Oct 22, 202412,121,567Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatasePharmaceuticalsREGENXBIO INC.
Aug 27, 202412,070,702Anion exchange chromatography for recombinant AAV productionChemical engineeringREGENXBIO INC.
Aug 27, 202412,070,510Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluidPharmaceuticalsREGENXBIO INC.
May 21, 202411,986,515Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS)PharmaceuticalsREGENXBIO INC.
Mar 28, 202311,613,739Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cellsPharmaceuticalsREGENXBIO INC.
Nov 28, 20179,827,295Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidasePharmaceuticalsREGENXBIO INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0367328METHODS OF MANUFACTURING MICRODYSTROPHIN GENE THERAPY CONSTRUCTSPharmaceuticalsREGENXBIO Inc.
Dec 4, 20252025/0367327TREATMENT OF DYSTROPHINOPATHIES WITH MICRODYSTROPHIN GENE THERAPY CONSTRUCTSPharmaceuticalsREGENXBIO Inc.
Dec 4, 20252025/0367326MICRODYSTROPHIN NUCLEIC ACID GENE THERAPY CONSTRUCTS AND USES THEREOFPharmaceuticalsREGENXBIO Inc.
Nov 6, 20252025/0339555FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS FORMULATIONS WITH AGGREGATE FORMATIONPharmaceuticalsREGENXBIO Inc.
Oct 23, 20252025/0326861VECTORIZED LANADELUMAB AND ADMINISTRATION THEREOFPharmaceuticalsREGENXBIO Inc.
Oct 16, 20252025/0320287TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabPharmaceuticalsREGENXBIO Inc.
Oct 9, 20252025/0312492MICRODYSTROPHIN GENE THERAPY ADMINISTRATION FOR TREATMENT OF DYSTROPHINOPATHIESPharmaceuticalsREGENXBIO Inc.
Sep 18, 20252025/0288697VECTORIZED ANTI-TNF-ALPHA INHIBITORS FOR OCULAR INDICATIONSPharmaceuticalsREGENXBIO Inc.
Sep 4, 20252025/0277004HYBRID AAV CAPSIDSBiotechnologyREGENXBIO Inc.
Sep 4, 20252025/0276097FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICSBiotechnologyREGENXBIO Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 25 · Biotechnology 15 · Analysis of biological materials 1 · Chemical engineering 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RGNX · research, not advice